Current Status on the Development of a Totally Implantable Biventricular Assist Device: The Baylor Gyro BVAD

Abstract

Objective: The Baylor Gyro BVAD® is under development with the final goal of establishing a totally implantable biventricular assist system (BVAD). The aim of this study was to evaluate the safety, reliability, and effectiveness of the device in a long-term in vivo model. Methods: The BVAD was implanted into eight calves for longer than 4 weeks in a biventricular bypass fashion, with the native heart remaining. Pump performance was assessed with the system's digital data acquisition unit. Postoperatively, anticoagulation was maintained with i.v. heparin perfusion (ACT≤ 250 sec) gradually replaced by coumadin. Treadmill exercise tests were performed daily following a 10-day reconvalescence period after surgery. Results: The animals were kept alive for 37 - 90 days. The pumps yielded average flows of 5.3 ± 1.1 l/min and 4.9 ± 0.7 l/min for the LVAD and RVAD, respectively. Power consumption was 8.2 ± 2.7 W and 9.6 ± 4.7 W at 1935 ± 123 rpm and 2015 ± 365 rpm, respectively. All cases exhibited low hemolysis; renal and liver function were kept normal throughout the experiments. The animals demonstrated no thromboembolic neurological symptoms and tolerated moderate treadmill exercise. Conclusion: The Baylor Gyro BVAD demonstrated effective and reliable in vivo performance with acceptable biocompatibility. Based on these studies, we conclude that the system will be suitable as a long-term totally implantable BVAD for uses intended for longer than two years.

Key words

Biventricular assist device - centrifugal blood pump - continuous-flow blood pump - animal studies

References

• 1 Frazier O H, Benedict C R, Radovancevic B, Bick R J, Capek P, Springer W E, Macris M P, Delgado R, Buja L M. Improved left ventricular function after chronic left ventricular unloading.  Ann Thorac Surg. 1996;  62 675-682
• 2 Pavie A, Leger P. Physiology of univentricular versus biventricular support.  Ann Thorac Surg. 1996;  61 347-349 discussion 357-358
• 3 Frazier O H, Rose E A, Macmanus Q, Burton N A, Lefrak E A, Poirier V L, Dasse K A. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device.  Ann Thorac Surg. 1992;  53 1080-1090
• 4 Arabia F A, Smith R G, Copeland J G. et al . Cost analysis of the Novacor left ventricular assist system as an outpatient bridge to heart transplantation.  ASAIO J. 1996;  42 M546-549
• 5 Yozu R, Golding L, Yada I, Harasaki H, Takatani S, Kawada S, Nose Y. Do we really need pulse? Chronic nonpulsatile and pulsatile blood flow: from the exercise response viewpoints.  Artif Organs. 1994;  18 638-642
• 6 Shoor P M, Hammill F S, Griffith L D, Dilley R B, Bernstein E F. Hemodynamic response to exercise in the unanesthetized calf with pulseless arterial flow.  Trans Am Soc Artif Intern Organs. 1980;  26 1-7
• 7 Ishitoya H, Kawamura M, Linneweber J, Motomura T, Ichikawa S, Nishimura I, Glueck J, Shinohara T, Nose Y. Titania gel reduces thrombin generation.  Artif Organs. 2002;  26 959-963